drugset / Trial / NCT02183155
Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary purpose of this study was to evaluate the effect of meloxicam tablets (7.5, 15 mg and 30 mg) with meloxicam placebo. Extended-release indomethacin capsules (75 mg) was an active control to assess trial sensitivity on bleeding time in healthy subjects. The secondary aim of this study was to assess effects of treatment on other platelet function and coagulation parameters.
Timeline
- Start
- 2000-05
- Primary completion
- 2000-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Indomethacin | Small molecule | 75 mg | — |
| Subject | Meloxicam | Small molecule | 7.5 mg | — |
| Subject | Meloxicam | Small molecule | 15 mg | — |
| Subject | Meloxicam | Small molecule | 30 mg | — |
Indications
No indication recorded.